Videos

Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Adam Talenfeld, MD, argued in favor of using transarterial chemoembolization alongside immune checkpoint blockade to treat patients with hepatocellular...

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, James Harding, MD, discussed results from the EMERALD-1 study which demonstrated that transarterial chemoembolization plus immune checkpoint blockade...

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Jennifer Wo, MD, discussed use of long course neoadjuvant radiation therapy for the treatment of patients with rectal cancer.

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Ryan Moy, MD, PhD, discussed first-line use of PD-1 inhibitors for the treatment of patients with gastroesophageal cancers.

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Samuel Cytryn, MD, discussed first-line use of claudin-18.2 inhibitors for patients with gastroesophageal cancers.

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that antibody drug conjugates are not ready to replace TROP-2 inhibitors as the standard of care for patients with lung cancers.